Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence

被引：79

作者：

Kolb, AJ

Kaplita, PV

Hayes, DJ

Park, YW

Pernell, C

Major, JS

Mathis, G

机构：

[1] Packard Inst Co, Meriden, CT 06450 USA

[2] Boehringer Ingelheim Pharmaceut Inc, R&D Ctr, Ridgefield, CT 06877 USA

[3] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England

[4] Merck & Co Inc, Merck Sharp & Dohme Res Labs, Rahway, NJ 07065 USA

[5] Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France

[6] Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England

[7] CIS Bio Int, Res & New Technol, F-30203 Bagnols Ceze, France

来源：

DRUG DISCOVERY TODAY | 1998年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/S1359-6446(98)01204-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tyrosine kinases are important therapeutic targets in drug discovery high-throughput screening programs. Homogeneous time-resolved fluorescence (HTRF) eliminates many of the problems associated with some conventional screening assay methodologies and this has made the development of tyrosine kinase HTRF assays an exciting prospect for pharmaceutical companies. The authors illustrate the utility of this technology in the light of experience within five pharmaceutical companies.

引用

页码：333 / 342

页数：10

共 17 条

[1] Development of a scintillation proximity assay for human cytomegalovirus protease using (33)phosphorous [J].